应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06978 永泰生物-B
未开盘 08-11 13:22:24
0.375
+0.000
0.00%
最高
0.375
最低
0.375
成交量
4,000
今开
0.375
昨收
0.375
日振幅
0.00%
总市值
2.32亿
流通市值
2.32亿
总股本
6.18亿
成交额
1,500
换手率
0.00%
流通股本
6.18亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
8月，真正的机会在这个方向！
中金财经 · 08-11 20:50
8月，真正的机会在这个方向！
永泰生物-B(06978)拟于8月21日召开董事会审议2026年中期业绩
公告速递 · 08-11 20:45
永泰生物-B(06978)拟于8月21日召开董事会审议2026年中期业绩
海外顶级学术会议密集来袭，国产创新药迎数据披露窗口，创新药ETF易方达（516080）昨日“揽金”1.62亿元
证券之星 · 08-11 19:16
海外顶级学术会议密集来袭，国产创新药迎数据披露窗口，创新药ETF易方达（516080）昨日“揽金”1.62亿元
杨德龙：科技“六大赛道”有望轮番表现 关注细分行业龙头机会
新浪基金 · 08-11 16:23
杨德龙：科技“六大赛道”有望轮番表现 关注细分行业龙头机会
创新药概念持续走强，我武生物涨近4%
证券之星 · 08-11 13:56
创新药概念持续走强，我武生物涨近4%
半年报验证创新药景气预期！T+0恒生创新药ETF华泰柏瑞（520500）聚焦产业链复苏机遇
新浪基金 · 08-11 11:40
半年报验证创新药景气预期！T+0恒生创新药ETF华泰柏瑞（520500）聚焦产业链复苏机遇
创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升
金吾财讯 · 08-11 11:15
创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升
A股三大股指早盘震荡下跌，创新药继续活跃，商业航天陷调整，港股科网股分化
华尔街见闻 · 08-11 10:10
A股三大股指早盘震荡下跌，创新药继续活跃，商业航天陷调整，港股科网股分化
创新药“中国首发”密集落地 新靶点、新机制、新疗法加速向中国集聚
格隆汇 · 08-11 07:42
创新药“中国首发”密集落地 新靶点、新机制、新疗法加速向中国集聚
上海：支持企业研发的创新药、现代中药和高端医疗器械全球注册认证并在当地实现销售
格隆汇 · 08-10 17:08
上海：支持企业研发的创新药、现代中药和高端医疗器械全球注册认证并在当地实现销售
上半年创新药BD交易破千亿美元，港股通创新药ETF易方达（159316）标的指数涨近3%
证券之星 · 08-10 10:42
上半年创新药BD交易破千亿美元，港股通创新药ETF易方达（159316）标的指数涨近3%
周期无常，创新药核心价值永不褪色
新浪基金 · 08-10 10:29
周期无常，创新药核心价值永不褪色
创新药概念股，集体爆发
中新经纬 · 08-10 10:15
创新药概念股，集体爆发
港股异动 | AI和创新药双向加持 剂泰科技-P(07666.HK)早盘涨超19% 继续领涨AI制药板块
智通财经 · 08-10 10:05
港股异动 | AI和创新药双向加持 剂泰科技-P(07666.HK)早盘涨超19% 继续领涨AI制药板块
龙头业绩轮番炸场，创新药8月“王者归来”？
新浪基金 · 08-10 09:08
龙头业绩轮番炸场，创新药8月“王者归来”？
创新药企业上半年营收大增 海外商业化成未来业绩看点
经济参考报 · 08-10 04:27
创新药企业上半年营收大增 海外商业化成未来业绩看点
破解胆管癌耐药世界难题 国产创新药获批上市
新华财经 · 08-09 13:24
破解胆管癌耐药世界难题 国产创新药获批上市
三大指数全线飘红，创新药、PCB概念掀涨停潮，机构建议逢低看多思路| 华宝基金3A日报（2026.8.7）
新浪基金 · 08-07
三大指数全线飘红，创新药、PCB概念掀涨停潮，机构建议逢低看多思路| 华宝基金3A日报（2026.8.7）
中报兑现+双目录+出海加速 创新药或迎多重驱动下的估值修复
中金财经 · 08-07
中报兑现+双目录+出海加速 创新药或迎多重驱动下的估值修复
片仔癀：公司长期坚持布局创新药赛道
证券之星 · 08-07
片仔癀：公司长期坚持布局创新药赛道
公司概况
公司名称：
永泰生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。
发行价格：
--
{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.375,"timestamp":1786425744827,"preClose":0.375,"halted":0,"volume":4000,"delay":0,"changeRate":0,"floatShares":618000000,"shares":618000000,"eps":-0.4884806967984933,"marketStatus":"未开盘","change":0,"latestTime":"08-11 13:22:24","open":0.375,"high":0.375,"low":0.375,"amount":1500,"amplitude":0,"askPrice":0.375,"askSize":35000,"bidPrice":0.37,"bidSize":50000,"shortable":0,"etf":0,"ttmEps":-0.4815024011299434,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.375,"openAndCloseTimeList":[[1786411800000,1786420800000],[1786424400000,1786435200000]],"volumeRatio":0.037127931731539034,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/wiki","defaultTab":"wiki","newsList":[{"id":"2658028918","title":"8月，真正的机会在这个方向！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658028918","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658028918?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:50","pubTimestamp":1786452609,"startTime":"0","endTime":"0","summary":"眼下的市场，一半火焰，一半海水。短期反弹还是会转化为中长期的反转，是当前的一个核心重点，科技股止跌，但内部分化加剧。创新药等非AI科技则纷纷启动新一轮上涨，但整体增量资金入场积极性较弱，市场又到了关键的窗口期。 主力资金在科技股与非科技之间加快轮动，这在今天的市场再一次鲜明体现。硬科技中的太极实业、洁美科技等均强势涨停，创新药中的甘李药业、药康生物等均创出新高。8月接下来真正的机会到底在哪里？","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/11/20260811164641.jpeg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/11/20260811164641.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260811/32332076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1147","09834","XLK","IBBQ","BK4588","02834","LNGR","07261","03034","MEDX","03455","BK1574","TTTN","BK4585","BK1161","07568","07266","03086","09086","07522","06978","VGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101667152","title":"永泰生物-B(06978)拟于8月21日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1101667152","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101667152?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:45","pubTimestamp":1786452326,"startTime":"0","endTime":"0","summary":"永泰生物製药有限公司（股票代码：06978）8月11日公告称，公司董事会计划于2026年8月21日（星期五）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及相关公告事宜。\n\\n\\n公告显示，公司现任董事会成员包括：主席兼执行董事谭錚；非执行董事杨帆、王瑞华、王东虎、杨昕、刘锐及曹冉；独立非执行董事王英典、吴智杰、彭素玖及张国光。\n\\n\\n公司强调，香港交易及结算所有限公司及香港联合交易所有限公司对本公告内容概不负责，并对其准确性或完整性不作任何声明或保证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992486","title":"海外顶级学术会议密集来袭，国产创新药迎数据披露窗口，创新药ETF易方达（516080）昨日“揽金”1.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658992486?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:16","pubTimestamp":1786447005,"startTime":"0","endTime":"0","summary":"截至收盘，恒生港股通创新药指数上涨0.3%，中证港股通医药卫生综合指数上涨0.3%，中证创新药产业指数上涨0.5%，中证生物科技主题指数上涨0.5%，沪深300医药卫生指数下跌0.4%。同花顺iFinD数据显示，创新药ETF易方达昨日获1.62亿元资金净流入。业内观点指出，中国创新药在国际舞台上的学术话语权正在不断提升。在2026年的ASCO年会上，中国创新药企累计拿下了94项口头报告，多项核心数据双双刷新历年纪录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026081100032744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","516080","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658399355","title":"杨德龙：科技“六大赛道”有望轮番表现 关注细分行业龙头机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2658399355","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658399355?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:23","pubTimestamp":1786436580,"startTime":"0","endTime":"0","summary":"去年年初我就提出科技“六大赛道”的观点。现在来看，这六大赛道轮番表现，成为AI时代真正受益的方向，包括芯片半导体、算力算法、人形机器人、商业航天、固态电池、生物医药等。建议大家把握住板块轮动，配置行业龙头股，抓住机会。我已经给大家指明，科技行情没有结束，并给大家提出了六大赛道；现在是行业轮动，大家可以在这六大赛道里面寻找龙头股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjsy/2026-08-11/doc-inimxrnm7544791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","PBOT","ROBT","BK4585","BK4588","IBBQ","06978","VGT","ARTY","RTOO","BK1574","WDRN","MEDX","IQM","UBOT","BK1161","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658964054","title":"创新药概念持续走强，我武生物涨近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658964054","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658964054?lang=zh_cn&edition=full","pubTime":"2026-08-11 13:56","pubTimestamp":1786427794,"startTime":"0","endTime":"0","summary":"8月11日，创新药概念盘中持续走强，我武生物一度涨近4%，触及25.98元/股。中泰证券表示，2026年以来，中国创新药产业逐步进入价值兑现阶段，行业逻辑由过去依赖BD事件催化，转向海外商业化、临床数据兑现及持续收入贡献，近期海外龙头药企财报持续验证中国创新资产价值，MNC对于中国创新药的战略定位逐渐提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026081100018659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1161","BK0239","159992","300357","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969144","title":"半年报验证创新药景气预期！T+0恒生创新药ETF华泰柏瑞（520500）聚焦产业链复苏机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969144","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969144?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:40","pubTimestamp":1786419600,"startTime":"0","endTime":"0","summary":"支持场内T+0的恒生创新药ETF华泰柏瑞7月以来日均成交额达23.4亿元，相较2026年上半年8.81亿元的日均成交额，资金活跃度显著攀升。交投踊跃之下，恒生创新药ETF华泰柏瑞截至8月10日最新份额、规模分别达22.12亿份、32.19亿元，今年以来产品份额增加76.68%，规模增加66.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-08-11/doc-inimxewr7636555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","LNGR","BK1161","MEDX","IBBQ","06978","BK1574","520500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","LU1951186391.HKD","LU0315179316.USD","06978","BK1515","LU0072913022.USD","BK1161","LNGR","IE00B031HY20.USD","HK0000306685.HKD","IE00B5MMRT66.SGD","LU1226287875.USD","BK1617","LU2328871848.SGD","01548","06160","01093","BK1588","03692","159992","HK0000320223.HKD","IE00B543WZ88.USD","LU2125910500.SGD","02359","06855","KURE","LU2039709279.SGD","LU1152091168.USD","BK1576","BK1521","09969","09688","IE00BZ08YS42.EUR","LU1226288170.HKD","IBBQ","LU0326950275.SGD","LU1226287792.SGD","LU1303224171.USD","LU1993786604.SGD","LU2242644610.SGD","MEDX","LU1813983027.USD","02228","IE00BZ08YR35.GBP","BK1583","02410","02268","IE00BZ08YT58.USD","LU2488822045.USD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965769","title":"A股三大股指早盘震荡下跌，创新药继续活跃，商业航天陷调整，港股科网股分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965769","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965769?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:10","pubTimestamp":1786414218,"startTime":"0","endTime":"0","summary":"A股创新药、CRO概念延续涨势，百花医药6连板，甘李药业涨停，长春高新、万邦医药、博瑞医药、亚太药业涨幅居前。商业航天概念早盘下挫，中国卫星逼近跌停，超捷股份、斯瑞新材跌超10%，神剑股份、电科蓝天、航天环宇、金风科技跌超7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3779141","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UFO","BK4585","IBBQ","399300","SPAX","BK4564","SPCM","SNK","LNGR","RKX","ASUP","BK1161","ORBX","WARP","KCAI","159992","SPCF","XSHP","ASTY","SPCG","GALX","SPCI","06978","VXUS","LOFF","WSPC","ELOL","MARS","XSPC","ROKT","SSPC","SPCU","FSPC","BK4588","LOFD","DIPR","SPAL","159982","SPCQ","BK1574","WAR","MEDX","SPCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950174","title":"创新药“中国首发”密集落地 新靶点、新机制、新疗法加速向中国集聚","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950174","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950174?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:42","pubTimestamp":1786405353,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658981293","title":"上海：支持企业研发的创新药、现代中药和高端医疗器械全球注册认证并在当地实现销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2658981293","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658981293?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:08","pubTimestamp":1786352902,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1574","BK1100","LGHT","PTH","159992","AGNG","LNGR","HART","RSPH","06978","IEIH","09996","BK1161","IBBQ","159883","BK1583","MEDX","GDOC","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658019786","title":"上半年创新药BD交易破千亿美元，港股通创新药ETF易方达（159316）标的指数涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658019786","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658019786?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:42","pubTimestamp":1786329734,"startTime":"0","endTime":"0","summary":"今日早盘，创新药板块再度活跃，截至10:17，恒生港股通创新药指数上涨2.9%，成份股中，云顶新耀上涨7.7%，远大医药上涨6.6%。近期，咨询服务机构沙利文在2026生命科学新投资高峰论坛上披露，2026年上半年，中国创新药对外授权交易潜在总额达1100亿美元，交易规模已经提前达到了2025年全年的八成。此外，在全球Top10的BD交易中，中国企业独占8席。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026081000007068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK1161","06978","516080","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658013186","title":"周期无常，创新药核心价值永不褪色","url":"https://stock-news.laohu8.com/highlight/detail?id=2658013186","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658013186?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:29","pubTimestamp":1786328940,"startTime":"0","endTime":"0","summary":"但这种周期性的情绪波动，丝毫不改真正优秀的创新药核心资产所锚定的长期内在价值。在8月这个火热的半年报披露季，创新药产业链的核心优质资产，正以超预期的业绩兑现，有力地论证了创新药赛道不可替代的底层价值。也就是说，一款创新药一旦建立真正的全球范围产品优势，其长期价值将由全球患者需求和国际市场份额共同定义。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-10/doc-inimuvrt2959631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1161","06978","159992","MEDX","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658160136","title":"创新药概念股，集体爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658160136","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658160136?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:15","pubTimestamp":1786328100,"startTime":"0","endTime":"0","summary":"10日早盘，A股医药板块持续走高，CRO、创新药等概念股集体大涨。个股方面，药康生物、海正药业两连板，海普瑞涨停，南模生物、美迪西等涨超10%，药石科技、康龙化成、药明康德等大涨。消息面上，药明康德公告，美国法院就公司的初步禁令动议作出裁决，挑战1260H认定期间免受不利影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608103836363646.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608103836363646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","IBBQ","BK1161","LNGR","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658015776","title":"港股异动 | AI和创新药双向加持 剂泰科技-P(07666.HK)早盘涨超19% 继续领涨AI制药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2658015776","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658015776?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:05","pubTimestamp":1786327542,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","07666","BK1161","BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658066506","title":"龙头业绩轮番炸场，创新药8月“王者归来”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658066506","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658066506?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:08","pubTimestamp":1786324080,"startTime":"0","endTime":"0","summary":"当周，药明康德AH股涨幅分别高达20.55%、19.66%。龙头领衔，创新药全链沸腾。龙头大哥药明康德携多家CXO企业已经用业绩和订单证明行业景气度，创新药企能否同样用超预期业绩来完成产业共振的双向验证。意料之中，创新药企没有让市场失望。全球创新药投融资回暖。一级市场融资交易活跃，将为创新药企业带来充足资金，也为CXO企业带来订单。本月中报业绩或将持续验证创新药正从 “故事期” 切换到 “兑现期”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-10/doc-inimuvrr1265247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","159992","BK1574","IBBQ","MEDX","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608090","title":"创新药企业上半年营收大增 海外商业化成未来业绩看点","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608090","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608090?lang=zh_cn&edition=full","pubTime":"2026-08-10 04:27","pubTimestamp":1786307228,"startTime":"0","endTime":"0","summary":"8月7日，受创新药企业及相关产业公司发布2026年上半年业绩预增消息影响，创新药板块全面上涨。记者注意到，国际业务份额增长正成为创新药企业营收的重要增长点。业内人士指出，随着中国越来越多创新药进入国际市场，中国创新药企业业绩将有大幅增长。7月中旬以来，A股上市创新药企业及相关企业纷纷披露半年报情况。受多家企业成绩单亮眼的影响，8月7日创新药板块大涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608103836021979.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608103836021979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","IBBQ","159992","MEDX","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658718286","title":"破解胆管癌耐药世界难题 国产创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2658718286","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658718286?lang=zh_cn&edition=full","pubTime":"2026-08-09 13:24","pubTimestamp":1786253076,"startTime":"0","endTime":"0","summary":"新华财经上海8月8日电（谷青竹）近日，国家药品监督管理局正式批准药捷安康的捷恩泰上市。该药物是首个中国自主研发以解决“胆管癌患者经FGFR抑制剂治疗耐药”难题的创新药。FGFR2融合是一类驱动肿瘤发生的基因重排变异，可见于多种实体瘤，其中肝内胆管癌是FGFR2融合发生率最高的癌种。数据显示，约25.2%的胆管癌患者出现FGFR2融合变异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835907614.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835907614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1574","LNGR","06978","BK1161","MEDX","IBBQ","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657614649","title":"三大指数全线飘红，创新药、PCB概念掀涨停潮，机构建议逢低看多思路| 华宝基金3A日报（2026.8.7）","url":"https://stock-news.laohu8.com/highlight/detail?id=2657614649","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657614649?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:53","pubTimestamp":1786096380,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-07/doc-inimnvkp4750318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PCB","BK1161","IBBQ","LNGR","BK1574","06978","BK4211","MEDX","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657618034","title":"中报兑现+双目录+出海加速 创新药或迎多重驱动下的估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657618034","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657618034?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:38","pubTimestamp":1786088297,"startTime":"0","endTime":"0","summary":"A股三大指数今日集体上涨，截止收盘，沪指涨1.02%，深证成指涨1.42%，创业板指涨1.35%。沪深京三市成交额接近2.7万亿，较昨日放量逾千亿。个股方面，上涨股票数量超过2800只，逾70只股票涨停。 医药板块今日走势强劲，主要受益于以下几方面因素。 此外进入中报季，多家创新药公司中报亮眼。 国金证券最新行业周报表示，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"us","thumbnail":"http://caiji.3g.cnfol.com/colect/202608/07/20260807331171.jpg","type":0,"news_type":0,"thumbnails":["http://caiji.3g.cnfol.com/colect/202608/07/20260807331171.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260807/32328867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06978","REVS","IBBQ","159992","CZA","MEDX","NIFE","BK1161","LCO","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657061825","title":"片仔癀：公司长期坚持布局创新药赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2657061825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657061825?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:36","pubTimestamp":1786088203,"startTime":"0","endTime":"0","summary":"片仔癀回复：尊敬的投资者您好，公司1.1类创新中药肠激安胶囊III期临床试验进展请查看公司2026年6月24日发布的《公司关于肠激安胶囊III期临床试验完成首例试验参与者入组的公告》，后续进展请您持续关注公司公告。ADC新药PZH3122目前处于临床前研究阶段，待取得临床试验许可后，公司将加快推进后续临床试验相关工作。公司长期坚持布局创新药赛道，对创新药保持持续性研发投入，后续还将持续丰富创新药研发管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700021277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK1161","BK1574","BK0196","600436","159992","06978","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0417},{"period":"1month","weight":-0.3056},{"period":"3month","weight":-0.5833},{"period":"6month","weight":-0.8541},{"period":"1year","weight":-0.9085},{"period":"ytd","weight":-0.872}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0611},{"period":"3month","weight":-0.0279},{"period":"6month","weight":-0.051},{"period":"1year","weight":0.03},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.015994},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.057223},{"month":8,"riseRate":0.571429,"avgChangeRate":0.018837},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}